• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gain Therapeutics Inc (NQ: GANX )

2.320 -0.180 (-7.20%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 351,319
Open 2.530
Bid (Size) 2.270 (10)
Ask (Size) 2.630 (6)
Prev. Close 2.500
Today's Range 2.300 - 2.552
52wk Range 0.8900 - 5.330
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Gain Therapeutics Presents Data at 36ᵗʰ EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2
October 23, 2024
From Gain Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
October 15, 2024
Via Benzinga

Performance

YTD
-36.00%
-36.00%
1 Month
+34.88%
+34.88%
3 Month
+137.02%
+137.02%
6 Month
-18.60%
-18.60%
1 Year
-19.16%
-19.16%

More News

Read More
Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
October 15, 2024
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Present at Michael J. Fox Foundation’s 16th Annual Parkinson’s Disease Therapeutics Conference
October 09, 2024
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024
October 07, 2024
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Participate at Upcoming Investor Conferences
October 03, 2024
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson’s Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers
September 30, 2024
From Gain Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
September 27, 2024
Via Benzinga
Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease
September 26, 2024
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson’s Disease Models Including Two Late-Breakers at Neuroscience 2024
September 19, 2024
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Participate at H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024
From Gain Therapeutics, Inc.
Via GlobeNewswire
Small-Cap Gain Therapeutics Stock Falls On Phase 1 Data From Its Lead Asset For Parkinson's Disease
August 29, 2024
Via Benzinga
Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease
August 29, 2024
From Gain Therapeutics, Inc.
Via GlobeNewswire
GANX Stock Earnings: Gain Therapeutics Misses EPS for Q2 2024
August 08, 2024
Via InvestorPlace
Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update
August 08, 2024
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Participate at BTIG Virtual Biotechnology Conference
August 01, 2024
From Gain Therapeutics, Inc.
Via GlobeNewswire
7 Sorry Biotech Stocks Set to Make Investors Sad
July 22, 2024
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
July 04, 2024
Via Benzinga
Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024
June 28, 2024
From Gain Therapeutics, Inc.
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
June 28, 2024
Via InvestorPlace
Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO
June 27, 2024
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease
June 27, 2024
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
June 25, 2024
From Gain Therapeutics, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Gain Therapeutics Inc. (NASDAQ: GANX) Releases Pricing of Underwritten Public Offering, Projected to Reach $11M
June 18, 2024
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
S&P 500 Edges Lower; RH Shares Plunge After Q1 Results
June 14, 2024
Via Benzinga
Topics Stocks
Exposures US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap